186 related articles for article (PubMed ID: 35655225)
1. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety analysis of Danggui Shaoyao Powder for the treatment of non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled clinical trial.
Huang Q; An Z; Xin X; Sun Q; Gao S; Lv S; Xu X; Yang S; Lu F; Yuan J; Zhao Y; Hu Y; Liu P; Feng Q
BMC Complement Med Ther; 2023 Apr; 23(1):126. PubMed ID: 37076843
[TBL] [Abstract][Full Text] [Related]
3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
4. Traditional Chinese medicine Lingguizhugan decoction treating non-alcoholic fatty liver disease with spleen-yang deficiency pattern: Study protocol for a multicenter randomized controlled trial.
Xu J; Wang R; You S; Zhang L; Zheng P; Ji G; Liu B
Trials; 2020 Jun; 21(1):512. PubMed ID: 32522273
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Qushi Huayu granule for hyperlipidemia: study protocol for a randomized, double-blind, placebo-controlled trial.
Sun Y; Hu N; Chen G; Wang Y; Hu Y; Ge M; Zhao Y
Trials; 2022 Feb; 23(1):104. PubMed ID: 35109888
[TBL] [Abstract][Full Text] [Related]
6. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
8. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
9. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
[TBL] [Abstract][Full Text] [Related]
10. Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
Lee HA; Moon H; Kim Y; Lee HA; Kim HY
Trials; 2023 Aug; 24(1):490. PubMed ID: 37533096
[TBL] [Abstract][Full Text] [Related]
11. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the Chinese herbal medicine Bu-Shen-Huo-Xue granule for the treatment of coronary heart disease: study protocol for a multicenter, randomized, double-blinded, placebo-controlled clinical trial.
Liu L; Wang J; Li J; Li X; Li R; Liu Y; Yang G; Mao Q; Wang L; Yao Z; Wang Y; Zong S; Liu C
Front Cardiovasc Med; 2024; 11():1293818. PubMed ID: 38895537
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
[TBL] [Abstract][Full Text] [Related]
14. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
Kessoku T; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Ogawa Y; Imajo K; Saigusa Y; Yamamoto K; Yamanaka T; Usuda H; Wada K; Yoneda M; Saito S; Nakajima A
BMJ Open; 2020 Sep; 10(9):e037961. PubMed ID: 32907904
[TBL] [Abstract][Full Text] [Related]
16. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
Ozaki A; Yoneda M; Kessoku T; Iwaki M; Kobayashi T; Honda Y; Ogawa Y; Imajo K; Sakai E; Taguri M; Yamanaka T; Iwasaki T; Kurihashi T; Saito S; Nakajima A
Contemp Clin Trials Commun; 2020 Mar; 17():100516. PubMed ID: 31956725
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
[TBL] [Abstract][Full Text] [Related]
18. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
[TBL] [Abstract][Full Text] [Related]
19. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
[TBL] [Abstract][Full Text] [Related]
20. Evaluation on immediate analgesic efficacy and safety of Kai-Hou-Jian spray (children's type) in treating sore throat caused by acute pharyngitis and tonsillitis in children: study protocol for a randomized controlled trial.
Ma YN; Zhong CL; Hu SY; Cai QH; Guo SX
Trials; 2021 Mar; 22(1):216. PubMed ID: 33736674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
